RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare...
DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing...
Enzolytics Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at...
Comprehensive test and notification program ensures safety and provides peace of mind for IMG clients, staff, and vendors at the...
PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activityRobust in vivo tumor regression observed with once daily oral...
– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma...
TH1902 anti-tumor post-treatment effect persists longer than with docetaxel aloneMONTREAL, April 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX:...
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and...
Study Confirms F-star’s Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and ActivationCAMBRIDGE, United Kingdom and...
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and...
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen...
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a...
-- Late-breaking presentation highlights preclinical data for AO-176 in T-ALL --BRISBANE, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Arch Oncology,...
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of circulating CD8+ T cells, after...
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies on track for 1H 2022...
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral LILRB2 expression relative to an...
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells...
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021 Inivata’s RaDaR® MRD...
– exoASO™-STAT6 mediated genetic reprogramming of tumor associated macrophages results in potent single-agent anti-tumor activity in multiple preclinical models; IND...